Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered after Cesarean Birth

Hiba J. Mustafa, Henry L. Wong, Mahmoud Al-Kofahi, Malinda Schaefer, Ashwin Karanam, Michael M. Todd

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE:To evaluate bupivacaine concentrations in maternal plasma and transfer into breast milk in women undergoing liposomal bupivacaine infiltration in the transversus abdominis plane after cesarean birth.METHODS:Prospective cohort study of healthy pregnant women who underwent cesarean birth at term followed by a transversus abdominis plane block using 52 mg bupivacaine hydrochloride 0.25% (20 mL) and 266 mg liposomal bupivacaine 1.3% (20 mL). Simultaneous blood and milk samples were collected in a staggered fashion, three to four samples per patient at the following timepoints after block administration: 2, 6, 12, 24, 48, 72, and 96 hours. Quantification of bupivacaine was performed by liquid chromatography-tandem mass spectrometry. Neonatal drug exposure was modeled by calculating milk/plasma area under the curve (AUC) ratios, neonatal dosage, and relative neonatal dosage of bupivacaine at each sampling time.RESULTS:Thirty patients were enrolled. Concentrations in breast milk peaked at 6 hours (mean 58 ng/mL), followed by constant and steady decline to low levels at 96 hours (mean 5.2 ng/mL). Maternal plasma concentrations had two peaks, first at 6 hours (mean 155.9 ng/mL) and then at 48 hours (mean 225.8 ng/mL), followed by steady decline. Milk/plasma AUC0-tratios ranged between AUC0-2of 0.45 (80% CI 0.38-0.52) and AUC0-96of 0.15 (80% CI 0.14-0.17). Neonatal dosage ranged between a mean of 355.9 ng/kg at 0-2 hours and a mean of 15,155.4 ng/kg at 0-96 hours. Relative neonatal dosage was less than 1% at all time intervals. No serious adverse reactions occurred in any neonate.CONCLUSION:Bupivacaine is excreted in breast milk after local infiltration of liposomal bupivacaine and bupivacaine hydrochloride mixture into transversus abdominis plane blocks after cesarean birth. Relative neonatal dosages of less than 1% (less than 10% is considered to be unlikely to be of clinical concern) suggest minimal risks for breastfeeding healthy, term neonates after the administration of this combination of local anesthetics to mothers.CLINICAL TRIAL REGISTRATION:ClinicalTrials.gov, NCT03526419.

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalObstetrics and gynecology
Volume136
Issue number1
DOIs
StatePublished - Jul 2020

Bibliographical note

Funding Information:
Research reported in this publication was supported by Thrasher Research Fund CON00000000080211. Each author has confirmed compliance with the journal’s requirements for authorship.

Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered after Cesarean Birth'. Together they form a unique fingerprint.

Cite this